Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
907
datasets available to search
ShareScore release 0.7.1
Dataset results
907 results for “HCV”
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
ClinicalTrials.gov study NCT03208244. IPD Sharing: YES. Countries: 1. Publications: 1.
Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)
ClinicalTrials.gov study NCT04427202. IPD Sharing: YES. Countries: 1. Publications: 2.
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
ClinicalTrials.gov study NCT02945150. IPD Sharing: YES. Countries: 1. Publications: 1.
Reducing Hepatitis C diagnostic disparities with a point of care assay for HCV antigen detection
Open the record for dataset details and reuse information.
Homology analysis of HCV sequences obtained from a dialysis unit of northeast India
<p>This is a homology analysis (by DNASTAR MegaAlign Version 5.00) of 29 HCV Sequences (5'UTR-Core region sequencing) obtained from a dialysis unit of a tertiary care teaching hospital in northeast India. It is a part of a manuscript titled- "Circulation of an atypical hepatitis C virus (HCV) strain in a dialysis unit in northeast India". </p>
Supplementary table with homology analysis of twenty nine HCV sequences ((5'UTR-Core region) )
<p>It is a supplementary data table with homology analysis of 29 HCV sequences ((5’UTR-Core region) obtained from a dialysis unit of a tertiary care teaching hospital of Northeast India (Assam). It is a part (supplementary data) of the manuscript titled - "Circulation of an atypical hepatitis C virus (HCV) strain in a dialysis unit in northeast India" </p>
Raw Data for the article: HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma
<p>Since its identification, HCV has been considered one of the main causes of hepatitis and liver cancer. Currently, the molecular mechanisms of HCC development induced by HCV infection have not been sufficiently clarified. The recent discovery of novel treatments that inhibit HCV replication gave rise to new questions concerning HCC mechanisms. In particular, the HCV eradication mediated by new direct-acting antiviral (DAAs) drugs does not exclude the possibility of <em>de novo</em> HCC development; this finding opened more questions on the interplay between liver cells and the virus. Different groups have investigated the pathways leading to cancer recurrence in patients treated with DAAs. For this reason, we tried to gain molecular insights into the changes induced by HCV infection in the target liver cells. In particular, we observed an increase in microRNA34a (miR34a) expression following HCV infection of HCC cell line Huh7.5. In addition, Huh7.5 treated with extracellular vesicles (EVs) from the previously HCV-infected Huh7.5 underwent apoptosis. Since miR34 expression was increased in Huh7.5 EVs, we hypothesized a paracrine mechanism of viral infection mediated by miR34a cargo of EVs. The balance between viral infection and cell transformation may raise some questions on the possible use of antiviral drugs in association with antineoplastic treatment.</p>
Ultra-short response-guided Hepatitis C treatment with sofosbuvir and daclatasvir: the SEARCH study HCV sequence data
<p><strong>Background</strong></p> <p>WHO has called for research into predictive factors for selecting persons who could be successfully treated with shorter durations of antiviral therapy for Hepatitis C. We evaluated early virological response as a means of shortening treatment and explored host, viral and pharmacokinetic contributors to treatment outcome.</p> <p class="MsoNormal"><strong><span>Methods</span></strong></p> <p class="MsoNormal"><span>Duration of sofosbuvir and daclatasvir (SOF/DCV)</span> was determined according to <span>day 2 (D2) virologic response</span> for <span>HCV genotype (gt) 1- or 6-infected adults in Vietnam with mild liver disease. Participants received 4 or 8 weeks of treatment according to whether D2 HCV RNA was above or below 500 IU/ml (standard duration is 12 weeks). Primary endpoint was sustained virological response (SVR12). Those failing therapy were retreated with 12 weeks SOF/DCV. Host IFNL4 genotype and viral sequencing was performed at baseline, with repeat viral sequencing if virological rebound was observed. Levels of SOF, its inactive metabolite</span> <span>GS-331007 and DCV were measured on day 0 and 28. </span></p> <p class="MsoNormal"><strong>Findings</strong></p> <p class="MsoNormal"><span>Of 52 adults enrolled, 34 received 4 weeks SOF/DCV, 17 got 8 weeks and one withdrew. SVR12 was achieved in 21/34 (62%) treated for 4 weeks, and 17/17 (100%) treated for 8 weeks. Overall, 38/51 (75%) were cured with first-line treatment </span><span>(mean duration of 37 days). Despite a high prevalence of putative </span>NS5A-inhibitor <span>resistance-associated substitutions (RAS), all first-line treatment failures were cured after retreatment (13/13). We found no evidence treatment failure was associated with host </span><span>IFNL4 genotype, viral</span><span> subtype, baseline RAS or DCV levels. SOF metabolite levels were higher in those failing 4-week therapy.</span></p> <p class="MsoNormal"><strong>Interpretation</strong></p> <p class="MsoNormal">Shortened SOF/DCV therapy with retreatment if needed, reduces DAA use while maintaining high cure rates. D2 virologic response alone does not adequately predict SVR12 with 4 weeks of treatment.</p>
Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
ClinicalTrials.gov study NCT01329978. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting
ClinicalTrials.gov study NCT02350569. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
ClinicalTrials.gov study NCT01726517. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Thera
ClinicalTrials.gov study NCT02607800. IPD Sharing: YES. Countries: 8. Publications: 1.
Intensive Models of HCV Care for Injection Drug Users
ClinicalTrials.gov study NCT01857245. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
ClinicalTrials.gov study NCT00991289. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
ClinicalTrials.gov study NCT02201940. IPD Sharing: YES. Countries: 9. Publications: 3.
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
ClinicalTrials.gov study NCT01732796. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV
ClinicalTrials.gov study NCT03652675. IPD Sharing: NO. Countries: 1. Publications: 2.
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
ClinicalTrials.gov study NCT01790633. IPD Sharing: YES. Countries: 1. Publications: 2.
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
ClinicalTrials.gov study NCT01359644. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
ClinicalTrials.gov study NCT02613871. IPD Sharing: YES. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.